Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NPS Pharmaceuticals (NPSP) On Watch on Amgen (AMGN) Sensipar News
February 26, 2013 12:12 PM ESTNPS Pharmaceuticals, Inc. (Nasdaq: NPSP) is on watch on news the FDA has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar after the recent death of a 14-year-old patient in a trial.... More
Trials of Amgen's (AMGN) Sensipar Halted Following Death - FDA
February 26, 2013 12:01 PM ESTThe U.S. Food and Drug Administration (FDA) has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar (cinacalcet hydrochloride) after the recent death of a 14-year-old patient in a trial. FDA continues to gather information on the circumstances surrounding the patients death. Sensipar is a medication used to decrease the release of parathyroid hormone (PTH) from the parathyroid gland. Sensipar lowers high PTH levels leading to lower calcium levels in the blood; when calcium levels are too low it can result in health problems. FDA has approved Sensipar for use... More
